Compare ADMA Biologics Inc (ADMA) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Zoom Video Communications, Inc. — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Zoom Video Communications, Inc. trades at $103.84 (market cap $31.10B). The key difference: Zoom Video Communications, Inc. is far larger — about 14× ADMA Biologics Inc's market cap, and Zoom Video Communications, Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ZM | |
|---|---|---|
Market Cap | $2.22B | $31.10B |
Sector | Health | Technology |
52-Week High | $20.38 | $111.88 |
52-Week Low | $7.60 | $69.96 |
Enterprise Value | $2.29B | $23.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Zoom Communications (ZM) trades at $103.75, down 3.22% on the day, near the analyst consensus low price target of $104.00. The stock shows a bullish technical trend per moving averages, though oscillators indicate overbought conditions. Fundamentally, revenue grew to $4.67 billion in 2025 with a strong net income margin of 41.99%, while recent earnings beat expectations in Q1 2026. Analyst sentiment is mixed with a 38.78% buy rating, and insider selling has been notable in recent weeks.
The outlook for ZM hinges on continued execution amid competitive pressures. Upside exists if the company meets Q2 2026 EPS expectations of $1.48 and sustains high profitability, but risks include insider selling trends and potential growth deceleration. The stock's valuation at a P/E of 15.62 appears reasonable if earnings growth persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
